Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

K. Muro, E. Van Cutsem, Y. Narita, G. Pentheroudakis, E. Baba, J. Li, M. H. Ryu, W. I. Wan Zamaniah, W. P. Yong, K. H. Yeh, K. Kato, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L. T. Chen, T. E. Nakajima, K. Shitara, H. Kawakami, T. TsushimaT. Yoshino, F. Lordick, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero, J. Y. Douillard

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer (GC) was published in 2016, and covered the management and treatment of local, locoregional, locally advanced and metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and The Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic GC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic GC representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

Original languageEnglish
Pages (from-to)19-33
Number of pages15
JournalAnnals of Oncology
Volume30
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Bibliographical note

Funding Information:
DA reports fees for consultancy from Bayer, Merck Serono, Roche, Servier, Sanofi and BMS. EB reports fees for consultancy from Takeda, Taiho, Yakult, Esai, Eli Lilly, Chugai, Dainihon-Sumitomo, Kyowahakko-Kirin, Daiichi-Sankyo, Sanofi, Merck Serono, Ono, Bristle-Myers Squibb, and Astellas; and research funding from Takeda, Taiho, Yakult, Esai, Eli Lilly, Chugai, Kyowahakko-Kirin, Daiichi-Sankyo, Merck Serono, Ono, Bristle-Myers Squibb, Astellas, Shionogi, Bayer, MSD, and Linical. BCC reports fees for consultancy from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Yuhan, Pfizer, Eli Lilly and Janssen, and research funding from Novartis, Bayer, AstraZeneca, MOGAM Institute, Don-A ST, Champions Oncology and Janssen. LTC reports fees for consultancy from ONO, BMS, MSD, Eli Lilly, PhamaEngine, Five Prime, Novartis and AstraZeneca; remuneration from ONO, BMS, MSD, Eli Lilly, PhamaEngine, TTY, SyncoreBio, Five Prime, Novartis, Astra Zeneca, Ipsen; research funding from Novartis, Pfizer, Merck Serono, Polaris, TTY, SyncoreBio, Celgene, BMS; and patent royalties/licensing fees from HuniLife; and is a board member of ScinoPharm Taiwan, Ltd. HK reports research funding from Chugai, Eisai, and Daiichi-Sankyo. KK reports fees for consultancy from MSD, ONO Pharmaceuticals, Beigene, and Oncolys biopharma; and research funding from MSD, Ono Pharmaceuticals, Shionogi, and Beigene. FL reports fees for consultancy from Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, and Astellas Pharma; honoraria from Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Elsevier, BioNTech AG, SERVIER, Infomedica, Merck KGaA, and Roche; research funding from Bristol-Myers Squibb, and fees for travel, accommodation and expenses from Bristol-Myers Squibb. EM is an advisor for Amgen, Bayer, Sanofi, Servier and Roche. HM reports consultancy fees for Bayer, Boehringer-Ingelheim, BMS, Celgene, Chugai, Daiichi-Sankyo, Dainihon-Sumitomo, Eisai, Janssen, Kowa, Kyowa-Kirin, Lilly, Merck-Serono, MSD, Novartis, Ono, Ohtsuka, Pfizer, Sanofi, Shire Japan, Taiho and Takeda and research funding from Asahi Kasei Pharma, Astellas, Bayer, Boehringer-Ingelheim, BMS, Chugai, Daiichi-Sankyo, Dainihon-Sumitomo, Eisai, Kyowa-Kirin, Lilly, MSD, Nihon Shiyaku, Novartis, Ono, Pfizer, Sanofi, Taiho, Taisho-Toyama, Takeda, Teijin Pharma and Yakult. KM reports fees for consultancy from Chugai, Eli Lilly, Takeda, Ono, Bayer, and Taiho; and research funding from Gilead Sciences, Merck Serono, Ono, Pfizer, Kyowa Hakko Kirin, Shionogi, Daiichi-Sankyo, and MSD. MN reports fees for consultancy from MSD Oncology, Singapore; and honoraria for talks from Taiho Pharmaceuticals May 2018, and MSD Oncology November 2019. TN reports fees for consultancy from Taiho Pharm., Sanofi, Chugai Pharm, Takeda Pharm, Sawai Pharm, Bayer, Bristol-Myers Squibb, Merck Serono, Ono Pharm, and Mochida Pharm; and research funding from Taiho Pharm., Chugai Pharm, Takeda Pharm, Sanofi, Merck Serono, Daiichi-Sankyo, Ono Pharm, MSD and Esai. MHR reports fees for consultancy from Novartis, Lilly, MSD, Bristol-Myers-Squibb, ONO, Taiho and DAEHWA pharm. ECS reports fees for consultancy from BMS, Servier, Celgene, Five Prime Therapeutics, and Gritstone Oncology. KS reports fees for consultancy from Astellas Pharma, Lilly, Bristol-Myers Squibb, Takeda, Pfizer and Ono Pharmaceutical; and research funding from Dainippon Sumitomo Pharma, Lilly, MSD, Daiichi-Sankyo, Taiho Pharmaceutical, Chugai Pharma, and Ono Pharmaceutical. JT reports fees for consultancy from Bayer, Boehringer-Ingelheim, Chugai, Genentech Inc., Ipsen, Lilly, MSD, Merck Serono, Merrimack, Merus, Novartis, Peptomyc, Pfizer, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, Seattle Genetics, Symphogen and Taiho. EVC reports fees for consultancy from Bayer, BMS, Celgene, Lilly, Merck KGaA, Novartis and Servier, and research funding from Amgen, Bayer, BMS, Celgene, Ipsen, Lilly, Merck, Merck KGaA, Novartis, Roche and Servier. WZWI reports fees for consultancy from Boehringer-Ingelheim Malaysia, ROCHE Malaysia, Eisei Malaysia, and Eli Lilly Malaysia; and research funding from Amgen Inc., ROCHE Inc. and Merck Inc. KHY reports fees for consultancy from Boehringer-Ingelheim, Takeda, Bristol-Myers-Squibb (BMS), Ono Pharmaceutical, MSD, Eli Lilly and Amgen; and honoraria from Boehringer Ingelheim, Takeda, Bristol-Myers-Squibb (BMS), Ono Pharmaceutical, MSD, Eli Lilly and Amgen. TY reports honoraria (lecture fees) from Sanofi K.K., Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K, and Merck Serono Co., Ltd; and grant/research funding from MSD K.K., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd, Chugai Pharmaceutical Co., Ltd, GlaxoSmithKline K.K. and Nippon Boehringer-Ingelheim Co., Ltd. WPY reports fees for consultancy from ASLAN, MSD, BMS, and Merck. JYD, JL, ZL, IMN, YN, GP and TT have declared no conflicts of interest.

Funding Information:
The authors would like to thank Ms C. Tada from the secretariat of JSMO and Ms K. Marinoni, ESMO Assistant, for their preparation and on-site assistance and support during the face-to-face meeting of experts in Kobe. Dr A. Kinsella, Cancer Communications and Consultancy Ltd, Knutsford, Cheshire, UK is acknowledged for her assistance in the preparation of the manuscript funded by JSMO.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS'. Together they form a unique fingerprint.

Cite this